Identification of human cytochrome P450 enzymes involved in the formation of 4-hydroxyestazolam from estazolam

Xenobiotica

Volumn 35, Issue 5, 2005, Pages 455-465

  Miura, M ^a   Otani, K ^b   Ohkubo, T ^c  

^a AKITA UNIVERSITY HOSPITAL   (Japan)

^b YAMAGATA UNIVERSITY HOSPITAL   (Japan)

^c HIROSAKI UNIVERSITY HOSPITAL   (Japan)

Author keywords

4 Hydroxyestazolam; CYP3A4; Estazolam

Indexed keywords

4 HYDROXYESTAZOLAM; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; DRUG METABOLITE; ERYTHROMYCIN; ESTAZOLAM; ITRACONAZOLE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CROSS REACTIVITY; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG STRUCTURE; DRUG TRANSFORMATION; ENZYME ANALYSIS; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IC 50; LIVER MICROSOME; MICHAELIS CONSTANT; NORMAL HUMAN; VOLUNTEER;

BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; ESTAZOLAM; HUMANS; HYDROXYLATION; KINETICS;

EID: 22944466361     PISSN: 00498254     EISSN: None     Source Type: Journal    
DOI: 10.1080/00498250500111612     Document Type: Article

References (32)

1. Ahonen J, Olkkola KT, Neuvonen PJ. 1996. The effect of the antimycotic itraconazole on the pharmacokinetics and pharmacodynamics of diazepam. Fundamental and Clinical Pharmacology 10:314-318.
2. Bourrie M, Meunier V, Berger Y, Fahre G. 1996. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. Journal of Pharmacology and Experimental Therapeutics 277:321-332.
3. Carlile DJ, Hakooz N, Bayliss MK, Houston JB. 1999. Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans. British Journal of Clinical Pharmacology 47:625-635.
4. Coller JK, Somogyi AA, Bochner F. 1999. Flunitrazepam oxidative metabolism in human liver microsomes: involvement of CYP2C19 and CYP3A4. Xenobiotica 29:973-986.
5. Dal Bo L, Verga F, Marzo A, La Commare P, De Vito ML. 1997. Gas Chromatographic assay for estazolam in human plasma and results of a bioequivalence study. Pharmacological Research 35:329-333.
6. Echizen H, Kawasaki H, Chiba K, Tani M, Ishizaki T. 1993. A potent inhibitory effect of erythromycin and other macrolide antibiotics on the mono-N-dealkylation metabolism of disopyramide with human liver microsomes. Journal of Pharmacology and Experimental Therapeutics 264:1425-1431.
7. Giancarlo GM, Venkatakrishnan K, Granda BW, von Moltke LL, Greenblatt DJ. 2001. Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: inhibition by sulfaphenazole, omeprazole, and ticlopidine. European Journal of Clinical Pharmacology 57:31-36.
8. Gorski JC, Jones DR, Hamman MA, Wrighton SA, Hall SD. 1999. Biotransformation of alprazolam by members of the human cytochrome P4503A subfamily. Xenobiotica 29:931-944.
9. Greenblatt DJ, Miller LG, Shader RI. 1990. Neurochemical and pharmacokinetic correlates of the clinical action of benzodiazepine hypnotic drugs. The American Journal of Medicine 88:18s-24s.
10. Greenblatt DJ, von Moltke LL, Harmatz JS, Ciraulo DA, Shader RI. 1993. Alprazolam pharmacokinetics, metabolism, and plasma levels: clinical implications. Journal of Clinical Psychiatry 54:4-11.
11. Greenblatt DJ, Wright CE, von Moltke LL, Harmatz JS, Ehrenberg BL, Harrel LM, Corbett K, Couniham M, Tobias S, Shader RI. 1998. Ketoconazole inhibition of triazolam and alprazolam clearance: differential kinetic and dynamic consequences. Clinical Pharmacology and Therapeutics 64:237-247.
12. Halpert JR, Guengerich FP, Bend JR, Correia MA. 1994. Selective inhibitors of cytochromes P450. Toxicology and Applied Pharmacology 125:163-175.
13. Hesse LM, Venkatakrishnan K, von Moltke LL, Shader PJ, Greenblatt DJ. 2001. CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam. Drug Metabolism and Disposition 29:133-140.
14. Ko JW, Sukhova N, Thacker D, Chen P, Flockhart DA. 1997. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metabolism and Disposition 25:853-862.
15. Machinist JM, Bopp BA, Anderson DJ, Granneman GR, Sonders RC, Tolman K, Buchi K, Rollins D. 1986. Metabolism of 14C-estazolam in dogs and humans. Xenobiotica 16:11-20.
16. Miura M, Ohkubo T, Sugawara K, Okuyama N, Otani K. 2002. Determination of estazolam in plasma by high-performance liquid chromatography with solid-phase extraction. Analytical Science 18:525-528.
17. Newton DJ, Wang RW, Lu AY. 1995. Cytochrome P450 inhibitors. Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metabolism and Disposition 23:154-158.
18. Obach RS, Baxter JG, Liston TE, Silber BM, Jones BC, MacIntyre F, Ranee DJ, Wastall P. 1997. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. The Journal of Pharmacology and Experimental Therapeutics 283:46-58.
19. Ono S, Hatanaka T, Hotta H, Satoh T, Gonzalez FJ, Tsutsui M. 1996. Specificity of substrate and inhibitor probes for cytochrome P450s: evaluation of in vitro metabolism using cDNA-expressed human P450s and human liver microsomes. Xenobiotica 26:681-693.
20. Otsuji Y, Okuyama N, Aoshima T, Fukasawa T, Kato K, Gerstenberg G, Miura M, Ohkubo T, Sugawara K, Otani K. 2002. No effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of estazolam. Therapeutic Drug Monitoring 24:375-378.
21. Perloff MD, von Moltke LL, Court MH, Kotegawa T, Shader RI, Greenblatt DJ. 2000. Midazolam and triazolam biotransformation in mouse and human liver microsomes: relative contribution of CYP3A and CYP2C isoforms. The Journal of Pharmacology and Experimental Therapeutics 292:618-628.
22. Phillips JP, Antal EJ, Smith RB. 1986. A pharmacokinetic drug interaction between erythromycin and triazolam. The Journal of Clinical Psychopharmacology 6:297-299.
23. Pierce MW, Shu VS. 1990. Safety of estazolam. The United States clinical experience. The American Journal of Medicine 88:12S-17S.
24. Rane A, Wilkinson GR, Shand DG. 1977. Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. The Journal of Pharmacology and Experimental Therapeutics 200:420-424.
25. Shou M, Mei Q, Ettore Jr MW, Dai R, Baillie TA, Rushmore TH. 1999. Sigmoidal kinetic model for two cooperative substrate-binding sites in a cytochrome P450 3A4 active site: an example of the metabolism of diazepam and its derivatives. The Biochemical Journal 340:845-853.
26. Venkatakrishnan K, Greenblatt DJ, von Moltke LL, Shader RI. 1998. Alprazolam is another substrate for human cytochrome P450-3A isoforms. The Journal of Clinical Psychopharmacology 18:256.
27. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. 2001. Human drug metabolism and the cytochromes P450: application and relevance of in vitro models. The Journal of Clinical Pharmacology 41:1149-1179.
28. Wilkinson GR, Shand DG. 1975. Commentary: a physiological approach to hepatic drug clearance. Clinical Pharmacology and Therapeutics 18:377-390.
29. von Moltke LL, Greenblatt DJ, Harmatz JS, Duan SX, Harrel LM, Cotreau-Bibbo MM, Pritchard GA, Wright CE, Shader RI. 1996. Triazolam biotransformation by human liver microsomes in vitro: effects of metabolic inhibitors and clinical confirmation of a predicted interaction with ketoconazole. The Journal of Pharmacology and Experimental Therapeutics 276:370-379.
30. Yasui N, Kondo T, Otani K, Furukori H, Kaneko S, Ohkubo T, Nagasaki T, Sugawara K. 1998. Effect of itraconazole on the single oral dose pharmacokinetics and pharmacodynamics of alprazolam. Psychopharmacology 139:269-272.
31. Yasui N, Otani K, Kaneko S, Ohkubo T, Osanai T, Sugawara K, Chiba K, Ishizaki T. 1996. A kinetic and dynamic study of oral alprazolam with and without erythromycin in humans: in vivo evidence for the involvement of CYP3A4 in alprazolam metabolism. Clinical Pharmacology and Therapeutics 59:514-519.
32. Yuan R, Flockhart DA, Balian JD. 1999. Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam. The Journal of Clinical Pharmacology 39:1109-1125.